Kolon Life Science announced on Monday that it requested the Ministry of Food and Drug Safety for permission to introduce to the domestic market Invossa, its treatment for osteoarthritis of the knee.
 
Invossa is a cell-mediated medicine that has a three-to-one ratio of normal cartilage cells to transgenic cartilage cells.
 
Invossa is the first gene therapy in the nation and the first allogeneic cell therapy in the world for which officials are seeking biologics license approval.
 
Gene therapy is a technique used to to treat disease by inserting corrective genes.
 
Cell therapy is a method in which cellular material is injected into a patient. In autologous cell therapy, cellular material from the patient is used while in allogeneic cell therapy, cells from a donor are used.